Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Lenalid 25

Anticancer-Cancer-Treatment-Natco-Lenalidomide-25mg-Lenalid

Availability: In stock

Special Price $ 325

BRAND : Lenalid 25
STRENGTH : 25mg
INGREDIENT : Anticancer-Cancer-Treatment-Natco-Lenalidomide-25mg-Lenalid
COMPANY NAME : Natco
COUNT : 30 Tablets



Description of Lenalid 25

Lenalid (Lenalidomide) is grouped as an immunomodulatory agent and also comes under the group of an antiangiogenic agent.

 Lenalidomide is a functional analogue of thalidomide.

Pharmacology of Lenalid 25

Pharmacodynamic:

Lenalid (Lenalidomide) is antiangiogenic drug, proinflammatory cytokines secretions are inhibited by Lenalidomide. It is a potent inhibitor of tumor necrosis factor α secretion.

This tumor necrosis factor enlarges cell immediate immunity by provocation of anti-CD3 stimulated T cells.

T cells prohibit trophic signals to angiogenic factors in cells.

This will inhibits the growth of myeloma cells by activation of cell cycle arrest and cell death occurs.

Pharmacokinetic:

Absorption:

Lenalid (Lenalidomide) is rapidly absorbed and absorption is not affected by food.

Normal Peak time: 0.6-1.5 hours; but in myeloma patient 0.5 to 4 hours.

Distribution:

The volume of distribution of Lenalid (Lenalidomide) is 76-85 L

The plasma protein binding of Lenalid (Lenalidomide) is 23-29%

Metabolism:

Unchanged form of Lenalid (Lenalidomide) is prevalently circulating in the body. Two identified metabolites like hydroxyl Lenalidomide and N-acetyl-Lenalidomide.

Excretion:

Route of elimination is through renal. The half life of Lenalid (Lenalidomide) is around 3 to 5 hours.

Indication of Lenalid 25

Lenalid (Lenalidomide) is predominantly used for the conditions like;

  • Multiple myeloma
  • Transfusion dependent myelodysplastic syndrome (MDS) patients with deletion of 5q cytogenetic deformity with or without cytogenetic abnormalities
  • Mantle cell lymphoma (MCL)

Dose & Dosage's of Lenalid 25

The strength of Lenalidomide is 25mg

The dosage of Lenalidomide is varying depending on the syndrome;

Myelodysplastic disease:

The adult dose of Lenalid (Lenalidomide) is 10mg should be taken as a single dose.

Depending on creatinine clearance level, dose of the Lenalidomide in renal impairment patient is recommended;

CrCl >60 ml/min: dose adjustment not necessary

 CrCl 30-60 ml/min: 5mg PO qDay

CrCl <30 ml/min (nondialysis dependent): 2.5mg PO qDay

CrCl <30 ml/min: In dialysis dependent patients, 2.5mg PO qDay on dialysis day

Multiple myeloma:

Lenalid (Lenalidomide) is combined with dexamethasone: 25mg orally once a day on day 1 to 21 of repeated 28 day cycles. The dose of dexamethasone is 40mg orally on day 1-4, 9-12, 17-20 of each 28 days cycle for first 4 cycles.

Maintenance therapy following stem cell transplant: 10mg once a day for 3 cycles, then it is increase to 15mg as a single dose.

Mantle cell lymphoma:

The recommended dose should be 25mg PO qDay on day 1-21repeated for 28 days.

CrCl 30-60 ml/min: 10mg PO qDay

CrCl <30ml/min: 15mg PO q48hr

Pediatric: safety and effectiveness has not been established under the age of <18 years.

Side Effects of Lenalid 25

Blood related problems

Neutropenia, thrombocytopenia, anemia, leucopenia, Lymphopenia, neutropenia

Gastrointestinal (GIT):

Diarrhea, constipation, nausea, gastroenteritis, abdominal pain, dyspepsia, toothache, hemorrhage

Pulmonary:

Bronchitis, Nasopharyngitis, cough, upper respiratory tract infection, dyspnea, pneumonia, pharyngitis, rhinitis, Epistaxis

General:

Fatigue

Asthenia

Pyrexia

Peripheral edema

Influenza

Non cardiac chest pain

Sepsis

Bacterial infection

Skin and subcutaneous:

Prurituses, rash, dry skin, hyperhidrosis, cellulitis, hirsutism, skin hyper pigmentation, Erythema

Musculoskeletal:

Muscle cramp, muscle spasm, back pain, arthralgia, bone pain, neck pain, joint swelling

Mental problems:

Insomnia, depression, anxiety, hallucination, erectile dysfunction

Nerve system:

Dizziness, tremor, headache, dysgeusia, peripheral neuropathy, paresthesia, hypoesthesia

Metabolic:

Decreased appetite, decreased weight, hypokalemia, anorexia, hypocalcaemia, dehydration, gout, hypophosphatemia, hyponatremia, hypomagnesaemia

Eye problems:

Blurred vision, cataract, blindness, ocular hypertension

Liver:

Hyperbilirubinaemia, increased ALT, AST, abnormal liver function

Genitourinary:

Urinary tract infection, dysuria, hyperuricemia, Hematuria, urinary retention

Endocrine:

Hyperglycemia, diabetes mellitus, hypothyroidism

CVS:

Deep vein thrombosis, hypertension, atrial fibrillation, myocardial infarction, angina pectoris

Oncologic:

Tumor flare, squamous cell carcinoma, basal cell carcinoma, myelodysplastic syndrome

Renal:

Renal failure, renal tubular necrosis

Hypersensitivity:

Angioedema

Contraindication of Lenalid 25

Lenalid (Lenalidomide) is contraindicated in pregnancy condition.

Severe hypersensitivity reactions like angioedema, Stevens Johnson syndrome, toxic epidermal necrolysis to Lenalidomide

Drug Interaction of Lenalid 25

Some list of medicine interacts with Lenalidomide;

Aspirin

Bortezomib

Carfilzomib

Gefitinib

Apixaban

Tamsulosin

Precaution of Lenalid 25

While using Lenalid (Lenalidomide), care should be taken

Do not recommended for pregnant women or become pregnant

Lenalidomide causes;

Hematologic toxicity

Venous and arterial thromboembolism

The safety and efficacy of Lenalidomide has not been established for patients who are younger than 18 years.

Usage & Safety profile of Lenalid 25 Pregnancy & Lactation

Lenalid (Lenalidomide) is comes under pregnancy category X

Lenalid should not be recommended for pregnant women and become pregnant.

Lenalid causes fetal death.

Storage of Lenalid 25

The storage of Lenalid tablet is between 20oC to 25oC (68oF to 77oF); excursion accepted to 15°C and 30°C (59°F and 86°F).